Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
GeneVentiv Therapeutics
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on developing treatments for blood diseases and disorders.
Sector
Subsector
Location
total rounds
total raised
Dystrogen Therapeutics
Dystrogen Therapeutics is a clinical-stage regenerative medicine company that focuses on rare diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Tramontane Therapeutics
Tramontane Therapeutics is a gene therapy company focused on developing treatments for prevalent metabolic and neurodegenerative diseases.
Sector
Subsector
Keywords
Sio Gene Therapies
Sio Gene Therapies is a clinical-stage biopharmaceutical company focused on gene therapy for neurodegenerative diseases.
Sector
Subsector
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Sarepta Therapeutics
announced date
price
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 08.05.2018. Their latest investor Jain Foundation. Their latest round Corporate Round
Sarepta Therapeutics
Sarepta Therapeutics is a biotechnology company that develops gene therapies and medicines for neuromuscular diseases.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors5
Number of lead investors
Number of investors
Jain Foundation
Jain Foundation
count Of Investments
count Of Exists
Brian Albrecht
Brian Albrecht joined Third Rock Ventures in 2015 and brings more than 12 years of biopharmaceutical drug discovery experience to the firm. As a principal, Brian focuses on new company formation and drug discovery due diligence. Prior to joining Third Rock, Brian built and led the medicinal chemistry department at Constellation Pharmaceuticals – pioneering epigenetic drug discovery research. As one of the first four Constellation employees, he was instrumental in building the foundation of the drug discovery product engine and was given increasing amounts of responsibility throughout his tenure. Under his leadership, Constellation’s medicinal chemistry group delivered two clinical assets. Prior to Constellation, Brian was a member of the medicinal chemistry department at Amgen. Brian is listed as a co-inventor on over 20 issued patents and a co-author on more than 30 publications. Brian earned his Ph.D. in organic chemistry from Colorado State University and his B.S. in chemistry from Lafayette College. Brian has found that despite living in Boston, it is easy to hide the fact that he is an avid Yankees fan…until now of course.
current job
Rev1 Ventures
Rev1 Ventures is a Midwest-based investor startup studio that provides capital and strategic services.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Tom Walker
Tom Walker has been the Chief Executive Officer of TechColumbus, Inc. since May 2012. Tom Walker served as the Chief Executive Officer and President of i2E, Inc. until July 2012 and also served as its Chief Operating Officer and Executive Vice President. Tom Walker was responsible for the design and implementation of statewide and national programs and resources to assist advanced technology companies and entrepreneurs in business creation and access to early stage capital. Tom Walker served as the Chief Executive Officer and President at TechColumbus, Investment Arm. He has 15 years of experience building business opportunities in software, information technology, life sciences, alternative energy and the advanced materials industry sectors. He has a proven track record of coaching executive teams, as well as, raising and managing sources of early risk capital for emerging growth companies. As a Founding Member of i2E, Tom Walker was a Leader in the vision, design and implementation of i2E's business units. He is responsible for the management of the Oklahoma Technology Commercialization Center and the Technology Business Finance Program, which are OCAST programs funded with state appropriations, as well as, the Reynolds Governor's Cup Collegiate Business Plan Competition and Seed Step Angels. Tom Walker served as the Chief Executive Officer and Executive Director of the Oklahoma Investment Forum for three years, where he managed the Southwest Capital Conference. He serves as an Advisor to the National Angel Capital Association, serves as an Adjunct Professor of Entrepreneurship at the University of Tulsa and is a reviewer for the Kauffman Foundation's eVenturing initiative. He served as an Editor and Publisher of the Future Value magazine. Tom Walker turned the financially failing organization around in one year and attracted in excess of $15 billion in venture capital from more than twenty states to the region. Prior to the formation of i2E, Tom Walker worked with Battelle Memorial Institute, where he managed the corporate business development for five national technology divisions of Battelle in the Oklahoma region. He was instrumental in the development of over $60 million in new technology development business, managed an advanced technology project portfolio that averaged $36 million over a six-year period and directly developed more than $15 million in scientific and engineering project sales. He is a frequent national and international speaker and advisor in the areas of building innovation and entrepreneurial infrastructures. Tom Walker serves on the Boards of National Angel Capital Educational Foundation, Leadership Oklahoma and the Oklahoma Alliance for Manufacturing Excellence. He served as Chairman of the 6th annual North American Angel Capital Summit and serves as Chairman of 7th annual Angel Capital Summit. He was recognized as one of the 2006 Oklahoma business leaders under the age of 40. Tom Walker holds a B.S. in Mechanical Engineering from the University of Oklahoma, and a Master's of Business Administration from Oklahoma City University. He is a graduate of the 27th Annual Venture Capital Institute and the 4th Annual Venture Capital Institute Graduate Program. He is a graduate of Leadership Oklahoma Class XVIII.
current job
Sarepta Therapeutics
Sarepta Therapeutics is a biotechnology company that develops gene therapies and medicines for neuromuscular diseases.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
People
Founders1
Michael Triplett
Michael Triplett is the Co-Founder and Co-Chair at Clarametyx Biosciences.
current job
Michael Triplett